Dosage of Apelix and a simple understanding of how to use it

Alpelisibas a specific inhibitor of phosphatidylinositol3-kinase (PI3K) has been successfully developed by Novartis and used in the treatment of breast cancer. Especially when used in combination with fulvestrant, it has shown significant efficacy in PIK3CA-mutated, hormone receptor (HR)-positive and human epidermal growth factor receptor-2 (HER2)-negative breast cancer patients, and has been approved for marketing worldwide.

The conventional dosage form of Apelvis is oral tablets, each tablet contains150mg of active ingredient. According to the latest treatment guidelines, patients are recommended to take 300 mg once daily as two 150 mg film-coated tablets. To ensure optimal drug absorption and reduce gastrointestinal discomfort, patients are advised to take the drug with a meal. In the case of coadministration of fulvestrant, the initial dose of fulvestrant is 500 mg given on days 1, 15, and 29 and monthly thereafter. Specific dosage adjustments should follow your physician's recommendations and prescribing information.

For patients who have difficulty swallowing, Apelvis tablets offer an alternative way of taking the drug. Patients can place the tablets in a drinking cup containing 60-120mL (2-4 ounces) of water, wait 5 minutes, crush the tablets, stir evenly, and drink immediately. To ensure that the medication is fully taken, the patient should add a small amount of water again and repeat the stirring and drinking steps.

If the patient misses the prescribed medication time, but can still take it with food within 9 hours of the usual medication time However, if this time window is exceeded, patients are advised to skip that day's dose and resume the dosing schedule at their normal time the next day. It is important to note that if a patient vomits after taking the drug, it is not recommended to take additional doses within the same day.